Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants
Coadministration with vepdegestrant doubled dabigatran exposure and resulted in a minor increase (11%) in rosuvastatin exposure in humans.
Authors
- Weiwei Tan (ORCID: https://orcid.org/0000-0001-8915-1152)
- Kenneth George Doyle
- Jennifer A. Winton
- Naihan Chen (ORCID: https://orcid.org/0000-0002-7145-0776)
- Kimberly C. Lee
- Constantino Kantaridis
- Derek Z. Yang (ORCID: https://orcid.org/0000-0002-3642-7757)
- Kyle Matschke (ORCID: https://orcid.org/0009-0003-2043-851X)
- Li Zhou (ORCID: https://orcid.org/0000-0002-6736-0057)
- Yuanyuan Zhang
Institutions
- Pfizer (United States) (US)
- Pfizer (Belgium) (BE)
- Arvinas (United States) (US)
- Pfizer (China) (CN)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1002/bcp.70198
- Citations
- 3
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Pfizer